tbuckley/cabot-search huggingface dataset:
Effect of distinct EGFR downstream pathways on resistance to dual EGFR/ErbB2 combined targeted therapy of lapatinib (LPT) and cetuximab (CTX).
Authors: John F. Deeken, Corinne Ramos, Mary Barcus, Jimmy J. Hwang, John Marshall, Deepa Suresh Subramaniam, Aiwu Ruth He, Tingting Zhuang, Rosemarie A. Hardesty, Michael J. Pishvaian
Journal: Journal of Clinical Oncology (2012)

91 Background: Resistance to EGFR therapy is poorly understood. We performed a phase I study in which pre- and post-treatment biopsies were profiled to assess the impact of CTX and LPT on downstream pathways that drive cancer progression. Methods: Between 10/2010 and 5/2012, 16 patients (pts) were enrolled in a 3+3 dose escalation trial, including: colon (7), lung (4), head and neck (3), and anal cancers (2). Prior EGFR therapy was allowed. CTX was 400mg/m 2 on D1, then 250 mg/m 2 weekly. LPT dose levels were 750 mg, 1000 mg, and 1250 mg daily. Cycles were 21 days in length; pts were assessed for response every 2 cycles. Pts underwent pre- and post-cycle 1 tumor biopsies. Biopsies were evaluated with a Reverse Phase MicroArray (RPMA) platform. Protein lysates were robotically immobilized in defined spots on nitrocellulose-coated slides; each printed array was then interrogated with a highly specific antibody. A total of 36 different proteins were analyzed, including total and phosphorylated EGFR, ErbB2, ErbB3, MET, IGF, MAPK, PI3K, Jak-Stat, and other subpathways. Relative baseline expression levels were determined, as were percent change in matched samples. Results: Of 12 pts evaluable for response, 2 had a partial response (PR), 5 had stable disease (SD), and 5 had disease progression (DP). Baseline tumor measurements of total ERK, p90RSK, and p38MAPK correlated with response (p&lt;0.05), with a trend towards significance between response and expression of pEGFR, pMEK, pNFKB, and p4EBP1 (p&lt;0.10). Nine patients had paired pre- and post-treatment biopsies. In tumors from pts with PR and SD, consistent down regulation of the EGFR pathway was detected. In the four patients with DP, up-regulation of distinct pathway components was detected, including of IGF (1 pt), Mek1/Erk (2 pts), mTOR (2 pts), and STAT3 (3 pts). Conclusions: A tumor profile was defined that correlated with clinical benefit to LPT+CTX. Resistance to this combination was due to upregulation of EGFR pathway components, components that are druggable. This analysis highlights the potential of personalizing therapy with combined EGFR therapies, and for adding additional targeted therapies to patients with resistant tumors.
The role of ST2 and ST2 genetic variants in schistosomiasis
Authors: Xin Long, Michelle Daya, Jianping Zhao, Nicholas Rafaels, Huifang Liang, Joseph Potee, Monica Campbell, Bixiang Zhang, Maria Ilma Araujo, Ricardo R. Oliveira, Rasika A. Mathias, Li Gao, Ingo Ruczinski, Steve N. Georas, Donata Vercelli, Terri H. Beaty, Kathleen C. Barnes, Xiaoping Chen, Qian Chen
Journal: Journal of Allergy and Clinical Immunology (2017)
Dysfunction of Bone Marrow Endothelial Progenitor Cells from Subjects with Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation Can be Improved By Atorvastatin
Authors: Minmin Shi, Yuan Kong, Yang Song, Yuqian Sun, Yu Wang, Xiaohui Zhang, Lanping Xu, Kaiyan Liu, Xiaojun Huang
Journal: Blood (2016)
Abstract 19498: Scavenger Receptor BI (SR-BI) Deficiency Uncouples Obesity From Glucose Intolerance in Mice
Authors: Menno Hoekstra, Amber B Ouweneel, Miranda Van Eck
Journal: Circulation (2015)

Introduction: Scavenger receptor BI (SR-BI) is a multi-purpose player in cholesterol metabolism. Interestingly, several studies in humans have suggested that a significant relationship exists between the presence of common variants in the SR-BI gene and a higher body mass index. We therefore evaluated the contribution of SR-BI to high fat diet-induced obesity in mice. Methods and Results: Male SR-BI knockout (SR-BI KO; N=10) and wild-type (WT; N=9) mice were fed a diet containing 45% energy as fat for 12 weeks. SR-BI KO mice exhibited a worsened metabolic plasma profile as compared to WT controls with higher fasting levels of free cholesterol (+111%; P&lt;0.001), cholesterol esters (+84%; P&lt;0.001), triglycerides (+40%; P&lt;0.01), and glucose (+20%; P&lt;0.01). Daily food intake was similar in the two types of mice; 4.5±0.3 g for SR-BI KO vs 4.1±0.3 g for WT. Importantly, the relative increase in body weight over time was significantly greater in SR-BI KO mice (+51%) as compared to WT controls (+33%; two-way ANOVA P&lt;0.001 for genotype). The exacerbated increase in body weight could be attributed to a higher white adipose tissue mass (correlation coefficient R=0.87; P&lt;0.001). High fat diet-fed WT mice were glucose intolerant, but remained resistant to atherosclerosis. In contrast, atherosclerotic lesions could be readily detected in the aortic root of SR-BI KO mice (6.9±1.5 x 10 3 μm 2 ; P&lt;0.001), while their glucose tolerance was remarkably higher compared to that of controls (oral glucose tolerance test AUC 484±68 mM.min for SR-BI KO vs 875±130 mM.min for WT; P&lt;0.05). SR-BI deficiency thus uncouples obesity from glucose intolerance in mice. Conclusions: Our studies for the first time show that a proper SR-BI function inhibits the development of obesity in mice. Furthermore, these data imply that SR-BI may serve as therapeutic target to overcome the glucose intolerance normally associated with the presence of (morbid) obesity.
Clinical and Epidemiological Characteristics of Multiple Myeloma (MM): Comparison Between Hematopoietic Stem Cell Transplantation (HSCT) and Conventional Chemotherapy,
Authors: Gemma Ramirez, Consuelo Gonzalez Garcia, Ma Sol Durán, Javier De La Rubia, Alfons Soler, Inmaculada Castillo, Manuel Jurado, Paz Ribas, Ma Carmen Menchaca Echevarría, Miguel T. Hernandez, Ma Dolores López García-Carreño, Asunción Echeveste Gutierrez, Alicia Bailén Garcia, Silvia López, Jose Baquero
Journal: Blood (2011)
Association Between Colorectal Cancer Mortality and Gradient Fecal Hemoglobin Concentration in Colonoscopy Noncompliers
Authors: Yi-Chia Lee, Sam Li-Sheng Chen, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Jean Ching-Yuan Fann, Shu-Lin Chuang, Tsung-Hsien Chiang, Chu-Kuang Chou, Han-Mo Chiu, Ming-Shiang Wu, Chien-Yuan Wu, Shu-Li Chia, Shu-Ti Chiou, Hsiu-Hsi Chen
Journal: JNCI Journal of the National Cancer Institute (2016)

To what extent the risk for colorectal cancer (CRC) death among noncompliers of colonoscopy is elevated following positive fecal immunological testing and whether the elevated risk varies with the fecal hemoglobin concentration (f-Hb) and location of CRC have not been researched.We used data on 59 389 individuals (4.0%) among 1 489 937 Taiwanese screenees age 50 to 69 years with f-Hb 20 μg hemoglobin or more per gram of feces from 2004 to 2009. They were classified into 41 995 who received colonoscopy and 10 778 who received no confirmatory examination; the latter was categorized into three risk groups according to f-Hb (20-49, 50-99, and 100+). Mortality from CRC as the primary end point was monitored until December 31, 2012.A 1.64-fold (95% confidence interval [CI] = 1.32 to 2.04) increased risk for CRC death for the noncolonoscopy group as opposed to the colonoscopy group adjusting for differences in baseline characteristics. A gradient relationship was noted between cumulative mortality and age- and sex-adjusted f-Hb categories with 1.31-fold (95% CI = 1.04 to 1.71), 2.21-fold (95% CI = 1.55 to 3.34), and 2.53-fold (95% CI = 1.95 to 3.43) increased risk, respectively, for the 20-49, 50-99, and 100+ risk groups in the noncolonoscopy group compared with the colonoscopy group. The noncolonoscopy group led to a statistically significant 1.75-fold increased risk (95% CI = 1.35 to 2.33) for CRC of the distal colon but a statistically nonsignificant 1.11-fold increased risk (95% CI = 0.70 to 1.75) for the proximal colon, compared with the colonoscopy group. When the comparator was limited to subjects whose colonoscopy was completed to the cecum, the statistically significantly elevated risk for CRC mortality was seen for both distal and proximal colon in the noncolonoscopy group.After a positive fecal immunochemical test, colonoscopy can reduce by about half the number of deaths from CRC. Among colonoscopy noncompliers, higher f-Hb is associated with an increased risk of mortality from CRC in a dose-response manner.
CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo
Authors: Gray Kueberuwa, Hannah Gornall, Erik Marcelo Alcantar-Orozco, Deborah Bouvier, Zainul Abedin Kapacee, Robert Edward Hawkins, David Edward Gilham
Journal: Journal for ImmunoTherapy of Cancer (2017)

<h3>Background</h3> Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate with favourable clinical outcomes. T cells of early differentiation possess an increased capacity for proliferation and therefore persistence, using these cells for ATCT could therefore lead to improved clinical outcomes. <h3>Method</h3> We describe a method to enrich T cells of early differentiation status using paramagnetic beads and antibodies targeting cells expressing C-C motif chemokine receptor 7 (CCR7). <h3>Results</h3> Selection of cells expressing CCR7 enriches T cells of bearing markers of early differentiation status. This was validated through analysis of an array of surface markers and an observed reduction in effector cell functions ex vivo. CCR7 selection resulted in dramatic 83.6 and 137 fold increases in circulating levels of CD4 and CD8 T cells respectively compared to non-sorted T cells 3&nbsp;weeks after adoptive transfer to NSG mice. We observed no significant difference in the engraftment levels of CCR7 or CD62L selected cells in the NSG mouse model. Comparison of cells ex vivo, however, suggests CCR7 selection is superior to CD62L selection in enriching T cells of early differentiation status. <h3>Conclusions</h3> CCR7 selection offers a means to enrich T cells of early differentiation status for ACTC. Together our data suggests that these T cells are likely to display enhanced engraftment and persistence in patients in vivo and could therefore improve therapeutic efficacy of ACTC.
Endocrine Late Sequelae in Long-Term Survivors of Childhood Non-Hodgkin Lymphoma
Authors: Marjolein van Waas, Sebastian J.C.M.M. Neggers, Mariel Lizet te Winkel, Auke Beishuizen, Rob Pieters, Marry M. van den Heuvel-Eibrink
Journal: Blood (2011)
Rapid Detection of Nucleophosmin (NPM1) Mutations to Determine Prognostic Implications in Acute Myeloid Leukemia Patients with a Normal Karyotype.
Authors: Seo-Jin Park, Hyun-Sook Chi, Kyung Ran Jun, Sook Kyoung Min, Seongsoo Jang, Chan-Jeoung Park, Kyoo Hyung Lee, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim
Journal: Blood (2009)
Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach
Authors: A Coppe, E I Andersson, A Binatti, V R Gasparini, S Bortoluzzi, M Clemente, M Herling, J Maciejewski, S Mustjoki, S Bortoluzzi
Journal: Leukemia (2017)

Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach
Brain and pancreatic metastases: a clinico-pathological comparison of various facets of the tumor heterogeneity in renal cell carcinoma_The BRAVE project
Authors: L. Derosa, L. Galli, G. Le Teuff, B. Chanez, A. Guida, F. Ruatta, G. Gwenaelle, L. Albiges, A. Falcone, B. Escudier
Journal: Annals of Oncology (2016)
Clinical verification of tumour immune microenvironment in eribulin chemotherapy for breast cancer
Authors: Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Kento Kurata, Tamami Morisaki, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Masahiko Ohsawa, Masaichi Ohira, Kosei Hirakawa
Journal: Annals of Oncology (2016)
A comparison of monthly symptom reports for older (≥ 70 years) versus younger (&lt; 70 years) women with recurrent ovarian cancer over 1 year.
Authors: Premal H. Thaker, Susan M. Sereika, Janet Arida, Robert P. Edwards, Heidi Donovan
Journal: Journal of Clinical Oncology (2015)

85 Background: Approximately 30% of ovarian cancer patients are 70 or older at diagnosis. Evidence to guide treatment in this age group is limited in the recurrent setting due to clinician concerns about toxicities and quality of life. Evidence based on patient-reported outcomes is scarce. The objective of this exploratory analysis is to compare patient-reported symptoms for women with recurrent ovarian cancer &gt; age 70 vs. &lt; age 70. Methods: Ancillary analysis of data from a 3-arm web-based symptom management RCT (NR010735; GOG-259). Eligibility criteria included recurrent or persistent ovarian, fallopian, or primary peritoneal cancer; experiencing 3 or more cancer or treatment-related symptoms. 497 women were accrued; of those, 60 (12%) were &gt; age 70. Monthly severity data for 11 cancer- and treatment-symptoms rated “at their worst in the past week” on a 0 to 10 Likert-type scale are included in this analysis. Time (linear, quadratic, and cubic), age (young vs. old), and time by age group interactions were evaluated using random coefficient modeling for each of the symptoms over 12 months. Results: In general, the severity of these selected symptoms declined significantly (p &lt; .05) either linearly (memory problems and anxiety) or nonlinearly (fatigue, pain, constipation, peripheral neuropathy, nausea, lack of appetite, depression, and sleep disturbances) over time, except for vomiting which did not demonstrate a significant change over time. Age effects or age by time interactions (significant, p &lt; .05, or a trend, .05 &lt; = p &lt; .10) were found for pain, constipation, peripheral neuropathy, vomiting, and sleep disturbances, with generally higher initial values for younger ( &lt; = 70 years) women for pain and sleep disturbances and higher overall means for younger women for vomiting. For constipation and peripheral neuropathy, the nonlinear change over time varied significantly by age group, with the decline over time being more precipitous for older women. Conclusions: A better understanding of the different propensity for symptoms based on age can help clinicians not only address them but also choose chemotherapies to minimize them.
Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer patients: a single Centre experience
Authors: E. Maccaroni, R. Bracci, R. Giampieri, F. Bianchi, L. Belvederesi, C. Brugiati, S. Pagliaretta, A. Della Mora, F. Tronconi, M. Pistelli, A. Pagliacci, N. Battelli, Z. Ballatore, M. De Lisa, R. Berardi
Journal: Annals of Oncology (2016)
Iron Overload Adversely Affects Survival and Increases Risk of Graft-Versus-Host Disease and Blood Stream Infections after Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Vinod Pullarkat, Suzette Blanchard, Bernard Tegtmeier, Andrew Dagis, Kathryn Patane, James Ito, Stephen J. Forman
Journal: Blood (2007)
135P A multicenter retrospective observation study about overall survival benefit of eribulin mesylate in comparison with taxane regimens for metastatic cancer patients
Authors: Y. Kikuchi, Y. Uchida, H. Kanauchi, T. Niwa, K. Nishioka, K. Tada, M. Hashimoto, H. Yasuda, H. Kawabata, Y. Seto, T. Ogawa
Journal: Annals of Oncology (2016)
Recurrent TET2 Mutations in Adult T Cell Leukemia (ATL) and Identification of a Single Nucleotide Polymorphism in TET2 Region Predisposing to ATL Development
Authors: Ambroise Marçais, Katia Hanssens, Laetitia Waast, Vahid Asnafi, Philippe Gaulard, Felipe Suarez, Laurence Benit, Patrice Dubreuil, Antoine Gessain, Claudine Pique, Olivier Hermine
Journal: Blood (2015)
Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL),
Authors: Michael Schmitt, Rudolf Trenschel, Herbert G. Sayer, Catarina Schneider, Aenne Glass, Inken Hilgendorf, Anne Treschl, Christian Junghanss, Kersten Borchert, Michael Koenigsmann, Jochen Casper, Dietrich Beelen, Mathias Freund, Christoph Kahl
Journal: Blood (2011)
Automated telephone reminders: Potential to improve adherence to adjuvant hormonal therapy among patients with breast cancer.
Authors: Virginia P. Quinn, Joanne E. Schottinger, Kelley R. Green, Craig T. Cheetham
Journal: Journal of Clinical Oncology (2012)

297 Background: As the U.S. population ages and life expectancy lengthens, the number of new estrogen receptor positive (ER+) breast cancer (bca) cases is expected to grow substantially from the current 150,000/year. Numerous studies show that adjuvant hormonal therapy (AHT) dramatically reduces bca recurrence (by 50%) and mortality (by 30%) among ER+ women. Daily treatment for 5 years is the recommended therapy. Yet, reports of under-utilization are alarming, ranging from 30% to more than 50%. Methods: We examined utilization of AHT among members of Kaiser Permanente Southern California, a nonprofit prepaid health care organization serving 3.6 million socio-economically diverse members. We identified 10,827 women diagnosed with bca between 2000 and 2007 from the plan’s SEER-affiliated cancer registry who were eligible for AHT. We used automated pharmacy records to assess uptake and utilization of AHT (primarily tamoxifen (TAM) and aromatase inhibitors (AIs)). Results: In this insured population, we found 14% of eligible bca survivors did not begin AHT. Among women who started AHT, over 30% had sub-optimal adherence defined as a medication possession ratio &lt;80%. Discontinuation of AHT, defined as &gt;90 days without medication, began in year 1 (7%) and reached 25% by year 5. To address this threat to quality bca care, the health plan recently initiated an innovative automated telephone reminder (ATR) system among women who filled at least 1 prescription for TAM. Each month, ATR calls are made to about 125 women &gt;18 years, who are overdue between 2 and 6 weeks for a refill, and who have not developed intolerance to TAM or switched to an AI. To date, ATR calls have generated no or few complaints. Next steps include evaluation of the impact of the system on adherence to TAM and, subsequently, AIs, and incorporation of electronic prompts to clinical staff for follow-up with non-responders. Conclusions: Monitoring and intervention for improving adherence to AHT needs to begin at initiation and continue across the 5 years of recommended therapy. AVR can reach large numbers of bca survivors and may have the potential to ensure they receive optimal benefit from these life-saving treatments.
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
Authors: M.A. Glaire, E. Domingo, L. Vermeulen, T. van Wezel, G.-J. Liefers, R.A. Lothe, A. Nesbakkend, S.A. Danielsen, I. Zlobec, V. Koelzer, M. Berger, S. Castellví-Bel, M. de Bruyn, M. Novelli, S. Tejpar, M. Delorenzi, R. Kerr, D. Kerr, I. Tomlinson, D.N. Church
Journal: Annals of Oncology (2016)
Differential Transactivation Activities of Sumoylated CCAAT Enhancer Binding Protein alpha (C/EBPα) p42 Versus p30 May Contribute in Part, to Aberrant C/EBPα Activity in Acute Leukemias.
Authors: Arati Khanna-Gupta, Matthew Silver, William Hankey, Hong Sun, Nancy Berliner
Journal: Blood (2007)
Development of RA101348, a Potent Cyclic Peptide Inhibitor of C5 for Complement-Mediated Diseases
Authors: Alonso Ricardo, Michelle Arata, Steven J DeMarco, Ketki Dhamnaskar, Robert Hammer, Kristopher Josephson, Kathleen Seyb, Sylvia Tobe, Zhaolin Wang, Hong Zheng, Douglas Treco
Journal: Blood (2014)
Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10
Authors: I. Kiss, J. Rodón, E. Grande Pulido, S.Y. Rha, S. Sathornsumetee, G. Hess, E. Eigendorff, D. Cesic, S. Sutradhar, B. Pramanik, T.M. Kim
Journal: Annals of Oncology (2016)
Improved Outcomes Using Tacrolimus/Sirolimus for graft Versus Host Disease prophylaxis with a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant for Myelofibrosis
Authors: David S. Snyder, Joycelynne Palmer, Karl Gaal, Anthony Selwyn Stein, Vinod Pullarkat, Nyana Vora, Ryotaro Nakamura, Firoozeh Sahebi, Stephen J Forman
Journal: Blood (2008)
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
Authors: Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, Mark Lunt, Roger Hesselstrand, Luc Mouthon, Alan Silman, Edith Brown, László Czirják, Jörg H W Distler, Oliver Distler, Kim Fligelstone, William J Gregory, Rachel Ochiel, Madelon Vonk, Codrina Ancuţa, Voon H Ong, Dominique Farge, Marie Hudson, Marco Matucci-Cerinic, Alexandra Balbir-Gurman, Øyvind Midtvedt, Alison C Jordan, Paresh Jobanputra, Wendy Stevens, Pia Moinzadeh, Frances C Hall, Christian Agard, Marina E Anderson, Elisabeth Diot, Rajan Madhok, Mohammed Akil, Maya H Buch, Lorinda Chung, Nemanja Damjanov, Harsha Gunawardena, Peter Lanyon, Yasmeen Ahmad, Kuntal Chakravarty, Søren Jacobsen, Alexander J MacGregor, Neil McHugh, Ulf Müller-Ladner, Gabriela Riemekasten, Michael Becker, Janet Roddy, Patricia E Carreira, Anne Laure Fauchais, Eric Hachulla, Jennifer Hamilton, Murat İnanç, John S McLaren, Jacob M van Laar, Sanjay Pathare, Susannah Proudman, Anna Rudin, Joanne Sahhar, Brigitte Coppere, Christine Serratrice, Tom Sheeran, Douglas J Veale, Claire Grange, Georges-Selim Trad, Christopher P Denton
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational approach to compare effectiveness of currently used treatment approaches. <h3>Methods</h3> This was a prospective, observational cohort study of early dcSSc (within three years of onset of skin thickening). Clinicians selected one of four protocols for each patient: methotrexate, mycophenolate mofetil (MMF), cyclophosphamide or 'no immunosuppressant'. Patients were assessed three-monthly for up to 24 months. The primary outcome was the change in modified Rodnan skin score (mRSS). Confounding by indication at baseline was accounted for using inverse probability of treatment (IPT) weights. As a secondary outcome, an IPT-weighted Cox model was used to test for differences in survival. <h3>Results</h3> Of 326 patients recruited from 50 centres, 65 were prescribed methotrexate, 118 MMF, 87 cyclophosphamide and 56 no immunosuppressant. 276 (84.7%) patients completed 12 and 234 (71.7%) 24 months follow-up (or reached last visit date). There were statistically significant reductions in mRSS at 12 months in all groups: −4.0 (−5.2 to −2.7) units for methotrexate, −4.1 (−5.3 to −2.9) for MMF, −3.3 (−4.9 to −1.7) for cyclophosphamide and −2.2 (−4.0 to −0.3) for no immunosuppressant (p value for between-group differences=0.346). There were no statistically significant differences in survival between protocols before (p=0.389) or after weighting (p=0.440), but survival was poorest in the no immunosuppressant group (84.0%) at 24 months. <h3>Conclusions</h3> These findings may support using immunosuppressants for early dcSSc but suggest that overall benefit is modest over 12 months and that better treatments are needed. <h3>Trial registration number</h3> NCT02339441.